Recent findings highlight the effectiveness of Mazdutide, a dual receptor agonist, in treating type 2 diabetes among Chinese adults. The results of two Phase 3 clinical trials have been published back-to-back in Nature, showing significant improvements in blood sugar control when compared to dulaglutide and placebo treatments. Research led by Professor Zhu Dalong from Nanjing University has contributed to this critical advancement. Additionally, related developments in the field include data from Innovent on an obesity drug for adolescents and Everest acquiring rights to a PCSK9 inhibitor.